Original Article
International Journal of Obesity (2006) 30, 1729–1736. doi:10.1038/sj.ijo.0803344; published online 18 April 2006
Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial
K Wynne1,3, A J Park1,3, C J Small1, K Meeran1, M A Ghatei1, G S Frost2 and S R Bloom1
- 1Department of Metabolic Medicine, Imperial College London, Hammersmith Hospital, London, UK
- 2Department of Dietetics, Imperial College London, Hammersmith Hospital, London, UK
Correspondence: Professor SR Bloom, Department of Metabolic Medicine, Imperial College London, 6th Floor Commonwealth Building, Hammersmith Hospital, Du Cane Road, London W12 ONN, UK. E-mail: s.bloom@imperial.ac.uk
3These authors contributed equally to the project.
Received 30 December 2005; Revised 4 March 2006; Accepted 13 March 2006; Published online 18 April 2006.
Abstract
Background:
Oxyntomodulin has recently been found to decrease body-weight in obese humans and may be a potential anti-obesity therapy.
Objective:
To determine whether oxyntomodulin alters energy expenditure, in addition to reducing energy intake, in 'free-living' overweight and obese volunteers.
Design:
Randomized double-blind controlled cross-over trial.
Setting:
Community and hospital-based.
Participants:
Fifteen healthy overweight and obese men and women (age: 23–49 years, BMI: 25.1–39.0 kg/m2). All volunteers completed the study protocol.
Interventions:
Four-day subcutaneous self-administration of pre-prandial oxyntomodulin, three times daily. Participants were advised to maintain their normal dietary and exercise regimen.
Measurements:
(1) Energy expenditure, measured by indirect calorimetry and combined heart rate and movement monitoring; (2) energy intake, measured during a study meal.
Results:
Oxyntomodulin administration reduced energy intake at the study meal by 128
29 kcal (P=0.0006) or 17.35.5% (P=0.0071), with no change in meal palatability. Oxyntomodulin did not alter resting energy expenditure; but increased activity-related energy expenditure by 143109 kcal/day or 26.29.9% (P=0.0221); total energy expenditure by 9.44.8% (P=0.0454) and physical activity level by 9.54.6% (P=0.0495). A reduction in body weight of 0.50.2% was observed during the oxyntomodulin administration period (P=0.0232).
Conclusion:
Oxyntomodulin increases energy expenditure while reducing energy intake resulting in negative energy balance. This data supports the role of oxyntomodulin as a potential anti-obesity therapy.
Keywords:
energy expenditure, activity, appetite, oxyntomodulin, proglucagon
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
REVIEWS
The obesity pipeline: current strategies in the development of anti-obesity drugs
Nature Reviews Drug Discovery Review (01 Nov 2006)
The role of oxyntomodulin and peptide tyrosine?tyrosine (PYY) in appetite control
Nature Clinical Practice Endocrinology & Metabolism Review (01 Nov 2006)
The role of oxyntomodulin and peptide tyrosine?tyrosine (PYY) in appetite control
Nature Clinical Practice Endocrinology & Metabolism Review (01 Nov 2006)
International Journal of Obesity Review
RESEARCH
Subcutaneous administration of ghrelin stimulates energy intake in healthy lean human volunteers
International Journal of Obesity Original Article
